课题基金 / 基金详情

项目摘要

项目成果

Charles Richard Esther的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 药代动力学/药效学核心(核心D)将提供分析资源 本申请中的每个项目都要测量药物浓度和相关的 不同样本类型中的生物标志物。这将主要通过使用质量 光谱分析方法,首席研究人员在这方面有丰富的专业知识。方法 已经开发出检测药物和药物代谢物的铅(P2176)和 Backup(P2114)化合物,并成功地用于评价这些化合物的药代动力学 当药物应用于呼吸道时。同样,测量相关生物标志物的方法有 已经开发出来,并在初步实验中产生了生物学上可信的结果。 此外,Core有能力在需要时添加新的生物标志物。
英文摘要
Abstract The Pharmacokinetics/Pharmacodynamics Core (Core D) will provide analytic resources to each of the Projects in this application to measure concentrations of drugs and relevant biomarkers within various sample types. This will primarily be accomplished using a mass spectrometric approach, with which the principal investigator has significant expertise. Methods to detect drug and drug metabolites have already been developed for both the lead (P2176) and backup (P2114) compounds and successfully utilized to assess the pharmacokinetics of these drugs when applied to the airways. Similarly, methods to measure relevant biomarkers have been developed and yield biologically plausible results in preliminary experiments. Furthermore, the Core has the capability of adding new biomarkers as the need arises.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A physiologically based pharmacokinetic model of human airway epithelia
  • 批准号:
    10670676
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2021
  • 负责人:
    Charles Richard Esther
  • 依托单位:
A physiologically based pharmacokinetic model of human airway epithelia
  • 批准号:
    10459416
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Charles Richard Esther
  • 依托单位:
A physiologically based pharmacokinetic model of human airway epithelia
  • 批准号:
    10372741
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Charles Richard Esther
  • 依托单位:
A targeted drug for the treatment of inflammation in cystic fibrosis lung disease
  • 批准号:
    9136899
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2016
  • 负责人:
    Charles Richard Esther
  • 依托单位:
海外基金